Drug Courts — Randomized Trial Evidence Base
National Institute of Justice / RAND Corporation / multiple jurisdictions · Multiple US cities · 1997
Summary
Drug courts emerged from the recognition that the standard prosecution model — charging, convicting, and incarcerating drug-involved offenders — was neither effective at reducing drug use nor cost-efficient. The alternative: treat addiction as a health problem requiring sustained treatment and judicial accountability, not a moral failure requiring punishment. The RCT evidence is among the strongest in criminal justice policy: participants in drug courts have 8–14 percentage point lower re-arrest rates than comparable offenders receiving standard prosecution. The mechanism combines treatment access, frequent accountability (drug tests, court appearances), and a working relationship with a judge who knows the defendant's progress. The cost evidence is equally compelling: drug court costs roughly $5,000 per participant; incarceration costs roughly $30,000 per year. The program is one of the clearest examples of an evidence-based reform that is simultaneously more effective and cheaper than the status quo.
Research question
"Do drug courts — which divert drug-involved offenders from incarceration into judicially supervised treatment — reduce recidivism and substance use more than standard prosecution?"
Methodology
Intervention
Eligible drug-involved defendants offered participation in drug court: intensive supervision with frequent drug testing, mandatory treatment, regular court appearances before the same judge, and graduated sanctions (brief detention) or rewards (reduced charges) based on compliance. Successful graduation leads to charges dismissed or reduced. RCTs compared drug court to standard prosecution and incarceration.
Assignment
Multiple randomized controlled trials; Mitchell et al. (2012) meta-analysis of 92 studies including 26 RCTs; key individual RCTs: Baltimore City Drug Treatment Court, Multnomah County, Brooklyn Treatment Court
Sample size
Pooled meta-analysis: ~13,000 participants across 92 studies
Primary outcome
Recidivism (re-arrest; re-conviction) at 1–3 year follow-up; drug use; incarceration days
Effect estimate
Recidivism: −8 to −14 pp vs. standard prosecution in RCTs; drug use: significant reduction while in program, mixed evidence of persistence; incarceration days: substantially fewer during supervision period; cost savings: $3,000–$13,000 per participant vs. incarceration
Decision
Drug courts grew from 1 (Miami, 1989) to 3,500+ courts serving 150,000 participants annually by 2019; replicated in UK, Australia, and Canada; National Drug Court Institute uses RCT evidence as evidence-based practice standard; model influenced Proposition 36 in California (treatment over incarceration) and federal Second Chance Act
Result
Positive
Recidivism: −8 to −14 pp vs. standard prosecution in RCTs; drug use: significant reduction while in program, mixed evidence of persistence; incarceration days: substantially fewer during supervision period; cost savings: $3,000–$13,000 per participant vs. incarceration
Evidence strength
Strong
Randomized trial, replicated across multiple sites or studies.
Replication status
Replicated
Institution
National Institute of Justice / RAND Corporation / multiple jurisdictions
Location
Multiple US cities
Year
1997
Policy area
Public Safety
Mechanism
Community engagement